≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Severe mental retardation

DOID EFO Endpoint Browser PheWeb

F5_SEVRET

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — F72
  • Hospital discharge: ICD-9 — 3181
  • Hospital discharge: ICD-8 — 313
  • Cause of death: ICD-10 — F72
  • Cause of death: ICD-9 — 3181
  • Cause of death: ICD-8 — 313

2 out of 7 registries used, show all original rules.

98

4. Check minimum number of events

None

98

5. Include endpoints

None

98

6. Filter based on genotype QC (FinnGen only)

94

Control definitions (FinnGen only)

Control exclude
F5_MENTRET

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
F70-F79
Name in latin
Retardatio mentalis gravis

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 5092 2194 2897
Only index persons 4034 1735 2299
Unadjusted period prevalence (%)
Whole population 0.07 0.06 0.08
Only index persons 0.08 0.06 0.09
Median age at first event (years)
Whole population 23.02 24.33 22.03
Only index persons 22.29 23.33 21.50

-FinnGen-

Key figures

All Female Male
Number of individuals 94 36 58
Unadjusted period prevalence (%) 0.02 0.01 0.03
Median age at first event (years) 18.93 16.65 20.34

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
98
Matched controls
980
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
F72.0
ICD-10 Finland
Severe mental retardation, with the statement of no, or minimal, impairment of behaviour
+∞
76.3
63
*
N03AG01
ATC
valproic acid; systemic, rectal
26.9
54.8
45
30
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
21.1
49.5
47
41
F79.0
ICD-10 Finland
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
+∞
44.1
39
*
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
12.9
35.2
46
63
N05BA01
ATC
diazepam; systemic, rectal
13.4
33.9
41
50
P85
ICPC
Mental retardation
+∞
33.2
30
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
12.1
28.9
36
45
N05BA09
ATC
clobazam; oral
54.2
28.4
33
9
F72.1
ICD-10 Finland
Severe mental retardation, significant impairment of behaviour requiring attention or treatment
+∞
26.2
24
*
G40.9
ICD-10 Finland
Epilepsy, unspecified
37.4
26.1
33
13
183
Kela drug reimbursment
Lamotrigin and topiramate
64.1
24.9
28
6
F79.9
ICD-10 Finland
Unspecified mental retardation, without mention of impairment of behaviour
+∞
22.8
21
*
N05CD08
ATC
midazolam; nasal, systemic
23.0
22.7
33
21
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
24.8
21.3
30
17
N03AX11
ATC
topiramate; oral
32.9
19.4
25
10
F71.0
ICD-10 Finland
Moderate mental retardation, with the statement of no, or minimal, impairment of behaviour
+∞
19.4
18
*
N03AX14
ATC
levetiracetam; systemic
19.1
18.8
29
21
F72.9
ICD-10 Finland
Severe mental retardation, without mention of impairment of behaviour
+∞
18.3
17
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
7.9
17.9
30
52
G40.4
ICD-10 Finland
Other generalized epilepsy and epileptic syndromes
77.5
17.4
19
*
L28
ICPC
Limited function/disability (L)
6.7
16.1
32
66
113
Kela drug reimbursment
Anxiety disorders associated with mental retardation
+∞
16.1
15
*
F70.0
ICD-10 Finland
Mild mental retardation, With the statement of no, or minimal, impairment of behaviour
+∞
15.0
14
*
N05AX08
ATC
risperidone; systemic
6.7
14.9
29
58
N03AG04
ATC
vigabatrin; oral
175.0
14.9
15
*
N03AX09
ATC
lamotrigine; oral
14.8
14.9
25
22
N03AF02
ATC
oxcarbazepine; oral
15.5
14.6
24
20
R56.8
ICD-10 Finland
Other and unspecified convulsions
7.0
14.4
26
48
A06AD11
ATC
lactulose; oral
6.5
14.1
28
57
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
6.7
14.1
27
53
N03AF01
ATC
carbamazepine; oral, rectal
22.4
14.1
20
11
J18.9
ICD-10 Finland
Pneumonia, unspecified
5.0
13.9
48
159
G40.89
ICD-10 Finland
Other epilepsy
33.8
13.5
17
6
M41.4
ICD-10 Finland
Neuromuscular scoliosis
+∞
12.8
12
*
F73.0
ICD-10 Finland
Profound mental retardation, with the statement of no, or minimal, impairment of behaviour
+∞
12.8
12
*
181
Kela drug reimbursment
Retigabine and vigabatrin
148.2
12.8
13
*
Z01.1
ICD-10 Finland
Examination of ears and hearing
4.9
12.6
38
112
RT274, ,
NOMESCO Finland
+∞
11.7
11
*
Z31.5
ICD-10 Finland
Genetic counselling
6.6
11.4
21
39
U04
ICPC
Incontinence urine
24.9
11.1
15
7
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
5.8
10.9
23
49
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.9
10.7
29
77
F79.1
ICD-10 Finland
Unspecified mental retardation, significant impairment of behaviour requiring attention or treatment
+∞
10.6
10
*
R5110, ,
SPAT
12.1
10.6
19
19
SPAT1262
SPAT
Handing over of treatment supplies
5.4
10.3
24
56
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
19.4
10.2
15
9
H50.30
ICD-10 Finland
Intermittent esotropy
24.6
9.6
13
6
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.4
9.4
21
47
SPAT1229
SPAT
Assessment of need for aid
11.2
9.2
17
18
JDB10
NOMESCO Finland
Percutaneous gastrostomy
27.0
9.2
12
5
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
13.4
8.9
15
13
R62.0
ICD-10 Finland
Delayed milestone
7.6
8.6
20
32
NAG53
NOMESCO Finland
Posterior or lateral fusion of thoracic spine with fixation, more than 3 vertebraea
98.1
8.6
9
*
G41.9
ICD-10 Finland
Status epilepticus, unspecified
98.1
8.6
9
*
N03AF03
ATC
rufinamide; oral
+∞
8.4
8
*
TJD20
NOMESCO Finland
Change of gastrostomy tube
36.7
8.2
10
*
R1260
NOMESCO Finland
Evaluation of communicative skills
20.4
7.8
11
6
N03AX18
ATC
lacosamide; systemic
20.4
7.8
11
6
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.3
7.7
23
65
3046, ,
Kela drug reimbursment
+∞
7.4
7
*
R1100
NOMESCO Finland
General evaluation of the need for rehabilitation
7.4
7.3
17
27
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
13.5
7.3
12
10
R1240
NOMESCO Finland
Social assessment of need and possibilities of rehabilitation
32.7
7.3
9
*
G03DC03
ATC
lynestrenol; oral
32.7
7.3
9
*
N03AX15
ATC
zonisamide; oral
32.7
7.3
9
*
F83
ICD-10 Finland
Mixed specific developmental disorders
8.6
7.2
15
20
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
18.3
6.9
10
6
R5140, ,
SPAT
43.2
6.9
8
*
WYA20
NOMESCO Finland
Home visit
24.5
6.8
9
*
RT490, ,
NOMESCO Finland
24.5
6.8
9
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.5
6.8
30
111
TPH04
NOMESCO Finland
Cathetrisation of vein
3.5
6.8
30
111
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.4
6.7
31
118
NA7EA
NOMESCO Finland
Scoliosis X-ray examination
15.7
6.5
10
7
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
15.7
6.5
10
7
WX408
NOMESCO Finland
General anesthesy, balanced
3.1
6.5
41
187
ADB00
NOMESCO Finland
Implantation of vagus nerve stimulating device
74.5
6.5
7
*
7803A
ICD-9 Finland
General symptoms, Convulsions
74.5
6.5
7
*
Z3229
NOMESCO Finland
Other healthcare associate professional
4.0
6.4
21
63
WYA30, ,
SPAT
19.6
6.4
9
5
N03AX22
ATC
perampanel; oral
28.7
6.3
8
*
G40.00
ICD-10 Finland
Benign childhood epilepsy with centrotemporal EEG spikes
28.7
6.3
8
*
Q02
ICD-10 Finland
Microcephaly
+∞
6.3
6
*
R5130, ,
SPAT
+∞
6.3
6
*
199
Kela drug reimbursment
Rufinamide
+∞
6.3
6
*
1530, ,
Kela drug reimbursment
+∞
6.3
6
*
N03AA02
ATC
phenobarbital; systemic
+∞
6.3
6
*
WKEHK, ,
NOMESCO Finland
+∞
6.3
6
*
N03AE01
ATC
clonazepam; systemic
9.6
6.3
12
14
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.1
6.3
35
149
R1250
NOMESCO Finland
Evaluation of functional capability
11.1
6.2
11
11
ZXE10
NOMESCO Finland
More than one and less than three hours
2.9
6.1
44
216

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
3.8e+00
3.7e+00
—
—
1.0e+50
4.3e+00
3.8e+00
cases:30.67%
controls:0.95%
cases:26.58%
controls:0.91%
—
—
—
—
cases:10.39%
controls:0.00%
cases:33.80%
controls:0.71%
cases:30.91%
controls:1.01%
23
7
52
730
21
7
58
760
—
—
8
0
69
763
24
5
47
701
17
6
38
588
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
3.1e+00
2.4e+00
—
—
—
2.5e+00
3.2e+00
cases:28.00%
controls:1.63%
cases:10.13%
controls:1.04%
—
—
—
—
—
—
cases:14.08%
controls:1.27%
cases:30.91%
controls:1.68%
21
12
54
725
8
8
71
759
—
—
—
10
9
61
697
17
10
38
584
Physical Medicine And Rehabilitation
25 [38004468]
2.0e+00
2.7e+00
—
—
—
2.8e+00
2.0e+00
cases:20.00%
controls:3.12%
cases:18.99%
controls:1.56%
—
—
—
—
—
—
cases:15.49%
controls:1.13%
cases:25.45%
controls:4.55%
15
23
60
714
15
12
64
755
—
—
—
11
8
60
698
14
27
41
567
oxcarbazepine; oral
N03AF02 [21604418]
2.7e+00
2.7e+00
—
—
—
2.4e+00
—
cases:14.67%
controls:1.09%
cases:8.86%
controls:0.65%
—
—
—
—
—
—
cases:7.04%
controls:0.71%
—
—
11
8
64
729
7
5
72
762
—
—
—
5
5
66
701
—
melatonin; oral
N05CH01 [21604659]
2.4e+00
2.5e+00
—
—
1.0e+50
2.8e+00
1.4e+00
cases:9.33%
controls:0.95%
cases:7.59%
controls:0.65%
—
—
—
—
cases:7.79%
controls:0.00%
cases:12.68%
controls:0.85%
cases:12.73%
controls:3.37%
7
7
68
730
6
5
73
762
—
—
6
0
71
763
9
6
62
700
7
20
48
574
Home Visit
OMOP4822459 [581476]
1.9e+00
2.0e+00
—
—
—
1.8e+00
1.8e+00
cases:25.33%
controls:4.75%
cases:12.66%
controls:1.96%
—
—
—
—
—
—
cases:14.08%
controls:2.55%
cases:27.27%
controls:5.72%
19
35
56
702
10
15
69
752
—
—
—
10
18
61
688
15
34
40
560
Paediatric neurology
421 [44777781]
1.4e+00
1.8e+00
1.7e+00
—
—
2.0e+00
1.7e+00
cases:33.33%
controls:10.72%
cases:27.85%
controls:5.74%
cases:6.33%
controls:1.17%
—
—
—
—
cases:28.17%
controls:4.82%
cases:23.64%
controls:5.22%
25
79
50
658
22
44
57
723
5
9
74
758
—
—
20
34
51
672
13
31
42
563
Neurology
13 [38004458]
1.7e+00
2.0e+00
—
1.0e+50
—
1.8e+00
1.4e+00
cases:18.67%
controls:4.21%
cases:13.92%
controls:2.22%
—
—
cases:8.86%
controls:0.00%
—
—
cases:12.68%
controls:2.41%
cases:21.82%
controls:6.57%
14
31
61
706
11
17
68
750
—
7
0
72
767
—
9
17
62
689
12
39
43
555
macrogol; oral
A06AD15 [21600575]
1.7e+00
2.2e+00
—
—
—
—
2.5e+00
cases:12.00%
controls:2.31%
cases:7.59%
controls:0.91%
—
—
—
—
—
—
—
—
cases:9.09%
controls:0.84%
9
17
66
720
6
7
73
760
—
—
—
—
5
5
50
589
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
3.1e+00
—
—
—
—
—
2.8e+00
cases:17.33%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
cases:18.18%
controls:1.35%
13
7
62
730
—
—
—
—
—
10
8
45
586
Treatment of a patient needing special arrangements
WYA30 [2001310874]
2.7e+00
—
—
—
—
—
2.6e+00
cases:18.67%
controls:1.49%
—
—
—
—
—
—
—
—
—
—
cases:21.82%
controls:2.02%
14
11
61
726
—
—
—
—
—
12
12
43
582
General Practice
1 [38004446]
7.0e-01
1.4e+00
2.3e+00
1.0e+50
—
1.5e+00
1.0e+00
cases:22.67%
controls:12.75%
cases:15.19%
controls:4.17%
cases:7.59%
controls:0.78%
cases:18.99%
controls:0.00%
—
—
cases:16.90%
controls:4.39%
cases:29.09%
controls:12.79%
17
94
58
643
12
32
67
735
6
6
73
761
15
0
64
767
—
12
31
59
675
16
76
39
518
risperidone; oral, parenteral
N05AX08 [21604559]
3.0e+00
—
—
—
—
—
2.2e+00
cases:12.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:12.73%
controls:1.52%
9
5
66
732
—
—
—
—
—
7
9
48
585
Outpatient Visit
OP [9202]
3.8e-01
4.0e-01
1.1e+00
3.8e+00
9.6e-01
6.7e-01
4.1e-01
cases:78.67%
controls:71.64%
cases:58.23%
controls:48.24%
cases:21.52%
controls:8.21%
cases:22.78%
controls:0.65%
cases:22.08%
controls:9.83%
cases:61.97%
controls:45.47%
cases:80.00%
controls:72.56%
59
528
16
209
46
370
33
397
17
63
62
704
18
5
61
762
17
75
60
688
44
321
27
385
44
431
11
163
Inpatient Hospital
21 [8717]
6.8e-01
1.3e+00
2.1e+00
1.0e+50
1.4e+00
1.3e+00
9.4e-01
cases:42.67%
controls:27.41%
cases:29.11%
controls:10.30%
cases:12.66%
controls:1.69%
cases:25.32%
controls:0.00%
cases:9.09%
controls:2.36%
cases:29.58%
controls:10.06%
cases:41.82%
controls:21.89%
32
202
43
535
23
79
56
688
10
13
69
754
20
0
59
767
7
18
70
745
21
71
50
635
23
130
32
464
Outpatient Hospital
22 [8756]
7.3e-01
1.2e+00
2.1e+00
1.0e+50
—
1.3e+00
8.8e-01
cases:34.67%
controls:20.35%
cases:18.99%
controls:6.39%
cases:8.86%
controls:1.17%
cases:6.33%
controls:0.00%
—
—
cases:22.54%
controls:7.08%
cases:30.91%
controls:15.66%
26
150
49
587
15
49
64
718
7
9
72
758
5
0
74
767
—
16
50
55
656
17
93
38
501
Functional capacity evaluation
443351003 [40481051]
2.1e+00
2.3e+00
—
—
—
—
—
cases:8.00%
controls:1.09%
cases:7.59%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
6
8
69
729
6
6
73
761
—
—
—
—
—
Emergency Room Visit
ER [9203]
5.6e-01
8.2e-01
2.6e+00
—
—
1.1e+00
3.0e-01
cases:46.67%
controls:33.38%
cases:20.25%
controls:10.04%
cases:16.46%
controls:1.43%
—
—
—
—
cases:25.35%
controls:9.77%
cases:32.73%
controls:26.43%
35
246
40
491
16
77
63
690
13
11
66
756
—
—
18
69
53
637
18
157
37
437
Ophthalmology
18 [38004463]
1.2e+00
1.4e+00
—
—
—
8.8e-01
1.1e+00
cases:36.00%
controls:14.38%
cases:22.78%
controls:6.65%
—
—
—
—
—
—
cases:15.49%
controls:7.08%
cases:34.55%
controls:15.49%
27
106
48
631
18
51
61
716
—
—
—
11
50
60
656
19
92
36
502
Pharmacy visit
OMOP4822462 [581458]
5.5e-01
1.0e+00
1.0e+00
1.5e+00
1.1e+00
1.3e+00
4.1e-01
cases:90.67%
controls:84.80%
cases:86.08%
controls:68.58%
cases:54.43%
controls:29.86%
cases:7.59%
controls:1.83%
cases:58.44%
controls:31.19%
cases:88.73%
controls:67.56%
cases:90.91%
controls:86.87%
68
625
7
112
68
526
11
241
43
229
36
538
6
14
73
753
45
238
32
525
63
477
8
229
50
516
5
78
CBC panel - Blood by Automated count
58410-2 [40761511]
2.9e-01
8.1e-01
2.1e+00
—
1.7e+00
1.3e+00
5.5e-01
cases:29.33%
controls:23.61%
cases:20.25%
controls:10.17%
cases:10.13%
controls:1.30%
—
—
cases:7.79%
controls:1.57%
cases:28.17%
controls:9.77%
cases:38.18%
controls:26.26%
22
174
53
563
16
78
63
689
8
10
71
757
—
6
12
71
751
20
69
51
637
21
156
34
438
Pediatric Surgery
OMOP4822020 [45756819]
4.6e-01
1.7e+00
—
—
—
1.5e+00
1.7e+00
cases:14.67%
controls:9.77%
cases:15.19%
controls:3.26%
—
—
—
—
—
—
cases:9.86%
controls:2.27%
cases:27.27%
controls:6.40%
11
72
64
665
12
25
67
742
—
—
—
7
16
64
690
15
38
40
556
Epilepsy, unspecified
G40.9 [45562083]
3.1e+00
—
—
—
—
—
—
cases:13.33%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
10
5
65
732
—
—
—
—
—
—
Case Management Agency
251B00000X [38004193]
2.4e-01
1.8e-01
1.0e-01
3.0e+00
6.9e-01
6.2e-01
5.0e-02
cases:70.67%
controls:65.54%
cases:62.03%
controls:57.76%
cases:27.85%
controls:25.81%
cases:27.85%
controls:1.83%
cases:36.36%
controls:22.28%
cases:70.42%
controls:56.09%
cases:72.73%
controls:71.72%
53
483
22
254
49
443
30
324
22
198
57
569
22
14
57
753
28
170
49
593
50
396
21
310
40
426
15
168
midazolam; nasal, oral, parenteral, sublingual
N05CD08 [21604643]
3.0e+00
—
—
—
—
1.0e+50
—
cases:12.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:8.45%
controls:0.00%
—
—
9
5
66
732
—
—
—
—
6
0
65
706
—
Supplier / Service Provider
OMOP5117446 [33004]
-9.5e-01
—
-1.0e+50
—
—
—
2.6e+00
cases:13.33%
controls:28.49%
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:12.73%
controls:1.01%
10
210
65
527
—
0
7
79
760
—
—
—
7
6
48
588
Epilepsy
G40 [45595935]
2.5e+00
—
—
—
—
—
—
cases:8.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
69
732
—
—
—
—
—
—
General evaluation of the need for rehabilitation
R1100 [2001310172]
2.5e+00
1.0e+50
—
—
—
—
—
cases:9.33%
controls:0.81%
cases:6.33%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
7
6
68
731
5
0
74
767
—
—
—
—
—
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
5.4e-01
5.7e-01
—
—
—
1.4e+00
1.1e+00
cases:17.33%
controls:10.85%
cases:8.86%
controls:5.22%
—
—
—
—
—
—
cases:15.49%
controls:4.39%
cases:29.09%
controls:11.78%
13
80
62
657
7
40
72
727
—
—
—
11
31
60
675
16
70
39
524
chlorhexidine
D09AA12 [21602275]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:1.01%
—
—
—
—
—
—
6
6
49
588
chlorhexidine
S03AA04 [21605193]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:1.01%
—
—
—
—
—
—
6
6
49
588
hydrocortisone
D07XA01 [21602180]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:1.01%
—
—
—
—
—
—
6
6
49
588
triamcinolone and antiseptics
D07BB03 [21602150]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:1.01%
—
—
—
—
—
—
6
6
49
588
hydrocortisone and antiseptics
D07BA04 [21602146]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:1.01%
—
—
—
—
—
—
6
6
49
588
chlorhexidine, combinations
D08AC52 [21602208]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:1.01%
—
—
—
—
—
—
6
6
49
588
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:1.01%
—
—
—
—
—
—
6
6
49
588
chlorhexidine
S02AA09 [21605155]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:1.01%
—
—
—
—
—
—
6
6
49
588
Epilepsy and comparable convulsive disorders
111 [2001600111]
2.4e+00
—
—
—
—
—
—
cases:9.33%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
68
730
—
—
—
—
—
—
oxazepam; oral
N05BA04 [21604569]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:7.04%
controls:0.71%
—
—
—
—
—
—
—
5
5
66
701
—
hydrocortisone; oral, parenteral
H02AB09 [21602737]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:1.18%
—
—
—
—
—
—
6
7
49
587
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
5.3e-01
8.9e-01
1.6e+00
—
2.2e+00
7.9e-01
5.5e-01
cases:34.67%
controls:23.74%
cases:26.58%
controls:12.91%
cases:10.13%
controls:2.22%
—
—
cases:16.88%
controls:2.23%
cases:25.35%
controls:13.31%
cases:41.82%
controls:29.29%
26
175
49
562
21
99
58
668
8
17
71
750
—
13
17
64
746
18
94
53
612
23
174
32
420
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
6.2e-02
2.1e+00
—
—
—
—
—
cases:9.33%
controls:8.82%
cases:8.86%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
7
65
68
672
7
9
72
758
—
—
—
—
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
5.0e-01
7.7e-01
1.5e+00
—
2.0e+00
7.8e-01
5.2e-01
cases:33.33%
controls:23.20%
cases:24.05%
controls:12.78%
cases:10.13%
controls:2.35%
—
—
cases:15.58%
controls:2.36%
cases:25.35%
controls:13.46%
cases:41.82%
controls:29.97%
25
171
50
566
19
98
60
669
8
18
71
749
—
12
18
65
745
18
95
53
611
23
178
32
416
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
9.9e-01
—
—
—
—
2.0e+00
7.0e-01
cases:8.00%
controls:3.12%
—
—
—
—
—
—
—
—
cases:9.86%
controls:1.42%
cases:10.91%
controls:5.72%
6
23
69
714
—
—
—
—
7
10
64
696
6
34
49
560
Vaccination
SPAT1325 [2001700426]
1.1e+00
—
—
—
—
—
2.0e+00
cases:14.67%
controls:5.56%
—
—
—
—
—
—
—
—
—
—
cases:14.55%
controls:2.19%
11
41
64
696
—
—
—
—
—
8
13
47
581
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-4.5e-02
7.1e-01
1.4e+00
—
1.9e+00
7.3e-01
3.9e-01
cases:25.33%
controls:26.19%
cases:21.52%
controls:11.86%
cases:10.13%
controls:2.61%
—
—
cases:14.29%
controls:2.36%
cases:22.54%
controls:12.32%
cases:40.00%
controls:31.14%
19
193
56
544
17
91
62
676
8
20
71
747
—
11
18
66
745
16
87
55
619
22
185
33
409
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
2.6e-01
1.9e+00
—
—
—
1.7e+00
1.7e+00
cases:12.00%
controls:9.50%
cases:8.86%
controls:1.43%
—
—
—
—
—
—
cases:8.45%
controls:1.70%
cases:10.91%
controls:2.19%
9
70
66
667
7
11
72
756
—
—
—
6
12
65
694
6
13
49
581
pH of Capillary blood
2745-8 [3009343]
2.6e-01
1.9e+00
—
—
—
1.7e+00
1.7e+00
cases:12.00%
controls:9.50%
cases:8.86%
controls:1.43%
—
—
—
—
—
—
cases:8.45%
controls:1.70%
cases:10.91%
controls:2.19%
9
70
66
667
7
11
72
756
—
—
—
6
12
65
694
6
13
49
581
General Practice Dentistry
1223G0001X [38003675]
1.9e+00
—
—
—
—
—
9.1e-01
cases:12.00%
controls:2.04%
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:3.87%
9
15
66
722
—
—
—
—
—
5
23
50
571
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
4.1e-01
4.7e-01
1.2e+00
—
1.8e+00
7.1e-01
4.4e-01
cases:30.67%
controls:22.66%
cases:21.52%
controls:14.60%
cases:10.13%
controls:3.13%
—
—
cases:15.58%
controls:2.88%
cases:25.35%
controls:14.31%
cases:41.82%
controls:31.65%
23
167
52
570
17
112
62
655
8
24
71
743
—
12
22
65
741
18
101
53
605
23
188
32
406
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
2.6e-01
1.8e+00
—
—
—
1.7e+00
1.6e+00
cases:12.00%
controls:9.50%
cases:8.86%
controls:1.56%
—
—
—
—
—
—
cases:8.45%
controls:1.70%
cases:10.91%
controls:2.36%
9
70
66
667
7
12
72
755
—
—
—
6
12
65
694
6
14
49
580
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
1.7e+00
—
—
—
—
-1.0e+50
—
cases:12.00%
controls:2.44%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
9
18
66
719
—
—
—
—
0
5
71
701
—
Examination of ears and hearing
Z01.1 [45547279]
8.0e-01
—
—
—
—
—
1.7e+00
cases:6.67%
controls:3.12%
—
—
—
—
—
—
—
—
—
—
cases:14.55%
controls:3.03%
5
23
70
714
—
—
—
—
—
8
18
47
576
Leukocytes [#/volume] in Urine
30405-5 [3018095]
5.0e-01
—
—
—
—
9.0e-01
1.5e+00
cases:13.33%
controls:8.55%
—
—
—
—
—
—
—
—
cases:7.04%
controls:2.97%
cases:21.82%
controls:5.89%
10
63
65
674
—
—
—
—
5
21
66
685
12
35
43
559
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.9e-01
6.3e-01
1.2e+00
—
1.5e+00
6.8e-01
4.3e-01
cases:37.33%
controls:32.97%
cases:34.18%
controls:21.64%
cases:13.92%
controls:4.43%
—
—
cases:19.48%
controls:5.24%
cases:35.21%
controls:21.67%
cases:50.91%
controls:40.40%
28
243
47
494
27
166
52
601
11
34
68
733
—
15
40
62
723
25
153
46
553
28
240
27
354
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.9e-01
6.3e-01
1.2e+00
—
1.5e+00
6.7e-01
4.2e-01
cases:37.33%
controls:32.97%
cases:34.18%
controls:21.64%
cases:13.92%
controls:4.43%
—
—
cases:19.48%
controls:5.24%
cases:35.21%
controls:21.81%
cases:50.91%
controls:40.57%
28
243
47
494
27
166
52
601
11
34
68
733
—
15
40
62
723
25
154
46
552
28
241
27
353
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.8e-01
6.3e-01
1.3e+00
—
1.5e+00
6.8e-01
4.2e-01
cases:37.33%
controls:33.24%
cases:34.18%
controls:21.64%
cases:13.92%
controls:4.30%
—
—
cases:19.48%
controls:5.24%
cases:35.21%
controls:21.53%
cases:50.91%
controls:40.57%
28
245
47
492
27
166
52
601
11
33
68
734
—
15
40
62
723
25
152
46
554
28
241
27
353
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.9e-01
6.3e-01
1.2e+00
—
1.5e+00
6.8e-01
4.2e-01
cases:37.33%
controls:32.97%
cases:34.18%
controls:21.64%
cases:13.92%
controls:4.43%
—
—
cases:19.48%
controls:5.24%
cases:35.21%
controls:21.67%
cases:50.91%
controls:40.57%
28
243
47
494
27
166
52
601
11
34
68
733
—
15
40
62
723
25
153
46
553
28
241
27
353
Platelets [#/volume] in Blood
26515-7 [3007461]
1.9e-01
6.3e-01
1.2e+00
—
1.5e+00
6.8e-01
4.3e-01
cases:37.33%
controls:32.97%
cases:34.18%
controls:21.64%
cases:13.92%
controls:4.43%
—
—
cases:19.48%
controls:5.24%
cases:35.21%
controls:21.53%
cases:50.91%
controls:40.40%
28
243
47
494
27
166
52
601
11
34
68
733
—
15
40
62
723
25
152
46
554
28
240
27
354
MCH [Entitic mass]
28539-5 [3035941]
1.9e-01
6.3e-01
1.2e+00
—
1.5e+00
6.8e-01
4.2e-01
cases:37.33%
controls:32.97%
cases:34.18%
controls:21.64%
cases:13.92%
controls:4.43%
—
—
cases:19.48%
controls:5.24%
cases:35.21%
controls:21.67%
cases:50.91%
controls:40.57%
28
243
47
494
27
166
52
601
11
34
68
733
—
15
40
62
723
25
153
46
553
28
241
27
353
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.7e-01
6.3e-01
1.2e+00
—
1.5e+00
6.8e-01
4.2e-01
cases:37.33%
controls:33.38%
cases:34.18%
controls:21.64%
cases:13.92%
controls:4.43%
—
—
cases:19.48%
controls:5.24%
cases:35.21%
controls:21.67%
cases:50.91%
controls:40.57%
28
246
47
491
27
166
52
601
11
34
68
733
—
15
40
62
723
25
153
46
553
28
241
27
353
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
6.7e-01
—
—
—
—
—
1.4e+00
cases:13.33%
controls:7.33%
—
—
—
—
—
—
—
—
—
—
cases:20.00%
controls:5.56%
10
54
65
683
—
—
—
—
—
11
33
44
561
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
6.9e-01
9.8e-01
—
—
—
—
1.4e+00
cases:13.33%
controls:7.19%
cases:8.86%
controls:3.52%
—
—
—
—
—
—
—
—
cases:21.82%
controls:6.40%
10
53
65
684
7
27
72
740
—
—
—
—
12
38
43
556
Protein/Creatinine [Ratio] in Urine
34366-5 [3045462]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
6
55
588
Internal Medicine
11 [38004456]
1.5e-01
8.2e-01
—
—
—
8.3e-01
4.3e-01
cases:14.67%
controls:12.89%
cases:11.39%
controls:5.35%
—
—
—
—
—
—
cases:11.27%
controls:5.24%
cases:21.82%
controls:15.32%
11
95
64
642
9
41
70
726
—
—
—
8
37
63
669
12
91
43
503
Extensive health check-up on fifth grade
SPAT1385 [2001700485]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
—
0
9
79
758
—
—
—
—
—
platelet aggregation inhibitors excl. heparin - combinations
B01AC30 [21601005]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
7
55
587
Depressive disorder
P76 [2002000870]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
0
5
75
732
—
—
—
—
—
0
6
55
588
Planned health check-up monitoring, health check-up performed based on individual need
SPAT1317 [2001700418]
-6.6e-02
-1.0e+50
—
—
—
—
—
cases:13.33%
controls:14.11%
cases:0.00%
controls:2.74%
—
—
—
—
—
—
—
—
—
—
10
104
65
633
0
21
79
746
—
—
—
—
—
Tension-type headache
G44.2 [45581495]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
Abdominal pain/cramps general
D01 [2002000300]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.02%
—
—
—
—
—
—
0
12
55
582
Bacteria identified in Urine by Culture
630-4 [3026008]
9.4e-01
—
—
—
—
—
1.1e+00
cases:6.67%
controls:2.71%
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:3.37%
5
20
70
717
—
—
—
—
—
5
20
50
574
Gas panel - Capillary blood
24337-8 [3022313]
1.5e-01
1.5e+00
—
—
—
—
—
cases:9.33%
controls:8.14%
cases:6.33%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
7
60
68
677
5
11
74
756
—
—
—
—
—
oseltamivir; oral
J05AH02 [21603179]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
75
730
—
—
—
—
—
—
Body mass index
60621009 [4245997]
-9.9e-01
—
-1.0e+50
—
—
—
1.0e+50
cases:12.00%
controls:26.87%
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:12.73%
controls:0.00%
9
198
66
539
—
0
6
79
761
—
—
—
7
0
48
594
Immunohistochemistry procedure
117617002 [4035726]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
75
725
—
—
—
—
—
—
Malignant neoplasm of prostate
C61 [45547509]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.36%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
cases:0.00%
controls:2.19%
0
10
75
727
0
7
79
760
—
—
—
0
8
71
698
0
13
55
581
Rheumatology
66 [38004491]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
cases:0.00%
controls:1.85%
—
0
7
79
760
—
—
—
0
8
71
698
0
11
55
583
CD3 cells/Lymphocytes in Blood
90304-7 [1175426]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
6
55
588
Psychiatric/psychological examination
SPAT1243 [2001700344]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
0
6
75
731
—
—
—
—
—
0
6
55
588
Specific gravity of Urine by Test strip
5811-5 [3000330]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
Feeling depressed
P03 [2002000800]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.02%
0
6
75
731
—
—
—
—
—
0
12
55
582
isosorbide mononitrate; oral
C01DA14 [21600324]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.49%
cases:0.00%
controls:1.17%
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
0
11
75
726
0
9
79
758
—
—
—
0
7
71
699
—
azelaic acid; ointment
D10AX03 [21602314]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
0
5
75
732
—
—
—
—
—
0
7
55
587
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
7
71
699
—
Fluoride application or other respective small prophylactic procedure
SCC01 [2001310310]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
Streptococcus pyogenes Ag [Presence] in Throat
18481-2 [3033319]
1.2e-01
-1.0e+50
—
—
—
—
—
cases:6.67%
controls:5.97%
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
5
44
70
693
0
8
79
759
—
—
—
—
—
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
0
5
71
701
—
ebastine; oral
R06AX22 [21603521]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
insulin aspart; parenteral
A10AB05 [21600719]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
0
9
77
754
—
—
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
6.1e-01
—
—
—
—
1.3e+00
7.8e-01
cases:12.00%
controls:6.92%
—
—
—
—
—
—
—
—
cases:11.27%
controls:3.40%
cases:20.00%
controls:10.27%
9
51
66
686
—
—
—
—
8
24
63
682
11
61
44
533
Thorax X-ray examination
GD1AA [2001303617]
9.5e-02
—
—
—
—
—
6.3e-01
cases:8.00%
controls:7.33%
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:5.05%
6
54
69
683
—
—
—
—
—
5
30
50
564
Anxiety disorder, unspecified
F41.9 [45542849]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.68%
0
8
75
729
—
—
—
—
—
0
10
55
584
Acute suppurative otitis media
H66.0 [45572040]
2.9e-01
1.9e+00
—
—
—
—
—
cases:8.00%
controls:6.11%
cases:6.33%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
6
45
69
692
5
8
74
759
—
—
—
—
—
Coloscopy
UJF32 [2001305029]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.44%
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:0.00%
controls:0.85%
cases:0.00%
controls:2.19%
0
18
75
719
0
6
79
761
—
—
—
0
6
71
700
0
13
55
581
Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid
22133-3 [3014973]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
telithromycin; oral
J01FA15 [21602983]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
Cough
R05 [45606792]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.02%
—
—
—
—
—
—
0
12
55
582
hydrochlorothiazide; oral
C03AA03 [21601466]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
0
5
75
732
—
—
—
—
—
0
7
55
587
hydrocortisone
A07EA02 [21600654]
5.3e-01
—
—
—
—
—
1.1e+00
cases:14.67%
controls:9.23%
—
—
—
—
—
—
—
—
—
—
cases:14.55%
controls:5.56%
11
68
64
669
—
—
—
—
—
8
33
47
561
Psychiatric family contact
IGP01 [2001304317]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.04%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.52%
0
15
75
722
—
—
—
—
—
0
9
55
585
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
290 [2001600222]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
Sex hormone binding globulin [Moles/volume] in Serum or Plasma
13967-5 [3004248]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
Doppler ultrasound examination of heart
FM1DE [2001303299]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.09%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
0
8
75
729
0
5
79
762
—
—
—
—
—
Hypersensitivity skin testing
268377001 [4147813]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
7
55
587
Genetic counselling
Z31.5 [45590715]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
0
7
79
760
—
—
—
0
5
71
701
—
Crossbite (anterior)(posterior)
K07.20 [2000502766]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
75
730
—
—
—
—
—
—
Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection
23826-1 [3012477]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.1e-01
2.5e-01
—
—
—
—
5.8e-01
cases:18.67%
controls:17.10%
cases:10.13%
controls:8.08%
—
—
—
—
—
—
—
—
cases:21.82%
controls:13.47%
14
126
61
611
8
62
71
705
—
—
—
—
12
80
43
514
allopurinol; oral, parenteral
M04AA01 [21604131]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
0
8
55
586
Cardiac ultrasound examination through oesophagus
FM1BE [2001303285]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.22%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
75
728
—
—
—
—
—
—
Striking against or struck by other object(s)
W22 [45756260]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.22%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
0
9
75
728
—
—
—
—
—
0
8
55
586
Wrist X-ray examination
ND1AA [2001307576]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
No procedures
SPAT1301 [2001700402]
9.5e-01
—
—
—
—
—
1.1e+00
cases:12.00%
controls:5.02%
—
—
—
—
—
—
—
—
—
—
cases:12.73%
controls:4.55%
9
37
66
700
—
—
—
—
—
7
27
48
567
Therapeutic intervention or check-up related to orthodontic treatment
SJX21 [2001310455]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.90%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
0
14
75
723
0
5
79
762
—
—
—
—
—
Acute tonsillitis, unspecified
J03.9 [45576942]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
0
6
75
731
—
—
—
—
—
0
8
55
586
fluticasone; inhalant
R03BA05 [21603288]
4.1e-01
—
-1.0e+50
—
—
—
7.0e-01
cases:8.00%
controls:5.43%
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:9.09%
controls:4.71%
6
40
69
697
—
0
6
79
761
—
—
—
5
28
50
566
sodium chloride
B05XA03 [21601198]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
Extraction of tooth
EBA00 [2001301923]
1.9e-01
-1.0e+50
—
—
—
—
1.0e+00
cases:9.33%
controls:7.87%
cases:0.00%
controls:1.83%
—
—
—
—
—
—
—
—
cases:18.18%
controls:7.58%
7
58
68
679
0
14
79
753
—
—
—
—
10
45
45
549
levocetirizine; oral
R06AE09 [21603498]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
cases:0.00%
controls:2.19%
—
0
8
79
759
—
—
—
0
8
71
698
0
13
55
581
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
—
6.5e-01
-1.0e+50
—
—
—
—
—
—
cases:6.33%
controls:3.39%
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
5
26
74
741
0
6
79
761
—
—
—
—
Physiotherapy
R4110 [2001310233]
1.0e+00
6.9e-01
—
—
—
1.1e+00
1.4e+00
cases:16.00%
controls:6.38%
cases:6.33%
controls:3.26%
—
—
—
—
—
—
cases:7.04%
controls:2.41%
cases:14.55%
controls:4.04%
12
47
63
690
5
25
74
742
—
—
—
5
17
66
689
8
24
47
570
ethylmorphine; oral
R05DA01 [21603397]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.04%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.02%
0
15
75
722
—
—
—
—
—
0
12
55
582
Prick test
37968009 [4242723]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
ibuprofen
R02AX02 [1588667]
-3.9e-01
6.9e-02
-1.0e+50
—
—
5.9e-01
-4.6e-01
cases:18.67%
controls:25.37%
cases:10.13%
controls:9.52%
cases:0.00%
controls:1.04%
—
—
—
—
cases:15.49%
controls:9.21%
cases:20.00%
controls:28.45%
14
187
61
550
8
73
71
694
0
8
79
759
—
—
11
65
60
641
11
169
44
425
clindamycin
D10AF01 [21602305]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
FEV1
20150-9 [3024653]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:0.00%
controls:0.85%
cases:0.00%
controls:1.01%
—
0
6
79
761
—
—
—
0
6
71
700
0
6
55
588
Removal and/or reactivation of orthodontic arch wire
SJD00 [2001310437]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.76%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
0
13
75
724
0
7
79
760
—
—
—
0
9
71
697
—
acrivastine; oral
R06AX18 [21603518]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.85%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:6.40%
0
21
75
716
—
—
—
—
—
0
38
55
556
Lump/swelling localized
S04 [2002000969]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
0
5
79
762
—
—
—
—
—
tamsulosin and dutasteride
G04CA52 [21602673]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
0
6
79
761
—
—
—
—
0
6
55
588
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
F79.0 [45566855]
1.0e+50
1.0e+50
—
—
—
1.0e+50
—
cases:18.67%
controls:0.00%
cases:17.72%
controls:0.00%
—
—
—
—
—
—
cases:12.68%
controls:0.00%
—
—
14
0
61
737
14
0
65
767
—
—
—
9
0
62
706
—
Isolated deficiency of growth hormone
E23.01 [2000501469]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.09%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
8
75
729
0
7
79
760
—
—
—
—
—
methylphenidate; oral
N06BA04 [21604757]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.30%
cases:0.00%
controls:0.91%
—
—
cases:0.00%
controls:0.79%
cases:0.00%
controls:1.70%
cases:0.00%
controls:3.03%
—
0
10
79
757
0
7
79
760
—
0
6
77
757
0
12
71
694
0
18
55
576
hydrocortisone aceponate
D07AC16 [21602135]
5.3e-01
—
—
—
—
—
1.1e+00
cases:14.67%
controls:9.23%
—
—
—
—
—
—
—
—
—
—
cases:14.55%
controls:5.56%
11
68
64
669
—
—
—
—
—
8
33
47
561
Pap smear
SPAT1193 [2001700294]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
6
55
588
Leukocyte morphology finding [Identifier] in Blood
11156-7 [3008757]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
75
730
—
—
—
—
—
—
Contusion of other parts of wrist and hand
S60.2 [45602941]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
Ambulatory ECG
XF404 [2001303370]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.22%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
75
728
—
—
—
—
—
—
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
0
5
79
762
—
—
—
—
—
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
0
5
71
701
—
gabapentin; oral
N02BF01 [955005]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
6
55
588
Other general examinations
Z00.8 [45581001]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
Predominantly allergic asthma
J45.0 [45557624]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
0
6
77
757
—
—
cycloSPORINE [Mass/volume] in Blood
3520-4 [3010375]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
75
729
—
—
—
—
—
—
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
0
5
79
762
—
—
—
—
0
9
55
585
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
0
5
79
762
—
—
—
—
0
8
55
586
Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.30%
—
—
—
—
—
—
—
—
—
—
—
0
10
79
757
—
—
—
—
—
Left side
ZXA05 [2001311347]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
0
5
79
762
—
—
—
—
—
rota virus, pentavalent, live, reassorted
J07BH02 [21601357]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
75
718
—
—
—
—
—
—
Follitropin [Units/volume] in Serum or Plasma
15067-2 [3023323]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.30%
—
—
—
—
—
—
cases:0.00%
controls:1.42%
cases:0.00%
controls:1.18%
—
0
10
79
757
—
—
—
0
10
71
696
0
7
55
587
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.73%
controls:2.86%
—
—
—
—
—
—
7
17
48
577
Other seropositive rheumatoid arthritis
M05.8 [45538634]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.84%
—
—
—
—
—
0
5
71
701
0
5
55
589
Yersinia sp identified in Stool by Organism specific culture
28549-4 [3014765]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
Burn/scald
S14 [2002000979]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
fluoxetine; oral
N06AB03 [21604711]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
0
9
55
585
Sleep apnoea
G47.3 [45562094]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.22%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.20%
0
9
75
728
—
—
—
—
—
0
19
55
575
Opiates [Presence] in Urine
3879-4 [3027008]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.36%
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.69%
0
10
75
727
0
6
79
761
—
—
—
—
0
16
55
578
androstanolone
G03BB02 [21602513]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
CD3-CD16+CD56+ (Natural killer) cells/cells in Blood
8112-5 [3027831]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
6
55
588
Dental calculus supragingival
K03.64 [2000502689]
2.9e-01
—
—
—
—
—
1.7e-01
cases:8.00%
controls:6.11%
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:7.74%
6
45
69
692
—
—
—
—
—
5
46
50
548
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
22
75
715
—
—
—
—
—
—
short-acting sulfonamides - combinations
J01EB20 [21602943]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
0
9
55
585
Health examination of person liable for military service
SPAT1321 [2001700422]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.17%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:4.38%
0
16
75
721
—
—
—
—
—
0
26
55
568
ECG with 12 standard connections
XF400 [2001303368]
5.0e-01
—
—
—
—
-1.0e+50
—
cases:8.00%
controls:5.02%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
6
37
69
700
—
—
—
—
0
7
71
699
—
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
0
8
55
586
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
0
6
79
761
—
—
—
—
—
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
7.9e-01
—
—
—
—
—
—
cases:10.67%
controls:5.16%
—
—
—
—
—
—
—
—
—
—
—
—
8
38
67
699
—
—
—
—
—
—
Respiratory infection other
R83 [2002000951]
6.5e-01
—
—
—
—
-1.0e+50
—
cases:8.00%
controls:4.34%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
6
32
69
705
—
—
—
—
0
7
71
699
—
Ear pain/earache
H01 [2002000475]
2.5e-01
—
—
—
—
—
—
cases:6.67%
controls:5.29%
—
—
—
—
—
—
—
—
—
—
—
—
5
39
70
698
—
—
—
—
—
—
Feeling ill
A05 [2002000146]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.17%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
0
16
75
721
0
7
79
760
—
—
—
0
8
71
698
—
omeprazole; oral, parenteral
A02BC01 [21600096]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:1.52%
—
—
—
—
—
—
5
9
50
585
combinations of corticosteroids
D07XB30 [21602188]
6.3e-01
5.8e-01
—
—
-1.0e+50
9.5e-01
1.1e+00
cases:16.00%
controls:9.23%
cases:6.33%
controls:3.65%
—
—
—
—
cases:0.00%
controls:0.66%
cases:7.04%
controls:2.83%
cases:20.00%
controls:7.91%
12
68
63
669
5
28
74
739
—
—
0
5
77
758
5
20
66
686
11
47
44
547
formoterol, glycopyrronium bromide and budesonide
R03AL11 [715850]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.09%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:1.52%
0
8
75
729
0
5
79
762
—
—
—
0
5
71
701
0
9
55
585
Photography of fundus of the eye or interpretation of photograph
SPAT1008 [2001700109]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
6
55
588
salbutamol; oral, parenteral
R03CC02 [21603312]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
0
5
79
762
—
—
—
—
—
Type 1 diabetes mellitus, With ophthalmic complications
E10.3 [45552380]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.22%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
0
9
75
728
—
—
—
—
0
6
71
700
—
Bile acid [Moles/volume] in Serum --fasting
35562-8 [3034274]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.22%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
75
728
—
—
—
—
—
—
hypromellose
S01KA02 [21605115]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.52%
0
7
75
730
—
—
—
—
—
0
9
55
585
Pollen allergy UNS
J30.19 [2000502595]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
enalapril and diuretics
C09BA02 [21601804]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.95%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:1.01%
0
7
75
730
0
5
79
762
—
—
—
0
5
71
701
0
6
55
588
Morphology [Interpretation] in Blood Narrative
18314-5 [3000093]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
Health check-up performed during second study year in students of upper secondary schools, vocational schools etc.
SPAT1364 [2001700465]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.37%
0
8
75
729
—
—
—
—
—
0
20
55
574
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
6.1e-01
—
—
—
—
1.3e+00
7.6e-01
cases:12.00%
controls:6.92%
—
—
—
—
—
—
—
—
cases:11.27%
controls:3.40%
cases:20.00%
controls:10.44%
9
51
66
686
—
—
—
—
8
24
63
682
11
62
44
532
Salmonella sp identified in Stool by Organism specific culture
20955-1 [3004716]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
0
8
75
729
—
—
—
—
—
0
8
55
586
pH of Urine
2756-5 [3015736]
—
—
—
—
—
1.4e+00
5.5e-01
—
—
—
—
—
—
—
—
—
—
cases:8.45%
controls:2.27%
cases:14.55%
controls:8.92%
—
—
—
—
—
6
16
65
690
8
53
47
541
Ultrasound examination of paranasal sinuses
SPAT1028 [2001700129]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
75
730
—
—
—
—
—
—
Student oral health check consistent with decree to assess need for oral health guidance and services
WYA50 [2001310877]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.53%
0
10
75
727
—
—
—
—
—
0
15
55
579
Eosinophils [#/volume] in Blood
26449-9 [3013115]
6.0e-02
1.8e-01
—
—
—
—
4.9e-01
cases:18.67%
controls:17.77%
cases:10.13%
controls:8.60%
—
—
—
—
—
—
—
—
cases:21.82%
controls:14.65%
14
131
61
606
8
66
71
701
—
—
—
—
12
87
43
507
IgG subclass 2 [Mass/volume] in Serum
2467-9 [3028192]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
Hypopituitarism
E23.0 [45561963]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
75
727
—
—
—
—
—
—
hydrocortisone
C05AA01 [21601608]
5.3e-01
—
—
—
—
—
1.1e+00
cases:14.67%
controls:9.23%
—
—
—
—
—
—
—
—
—
—
cases:14.55%
controls:5.56%
11
68
64
669
—
—
—
—
—
8
33
47
561
Right side
ZXA00 [2001311346]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:3.93%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.36%
0
29
75
708
0
7
79
760
—
—
—
—
0
14
55
580
hydrocortisone
D07AA02 [21602102]
5.3e-01
—
—
—
—
—
1.1e+00
cases:14.67%
controls:9.23%
—
—
—
—
—
—
—
—
—
—
cases:14.55%
controls:5.56%
11
68
64
669
—
—
—
—
—
8
33
47
561
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
—
—
—
—
—
—
5.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:5.39%
—
—
—
—
—
—
5
32
50
562
Glutamate decarboxylase 65 Ab [Units/volume] in Serum
13926-1 [3020148]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
Memory disturbance
P20 [2002000816]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
6
55
588
dextromethorphan, combinations; oral
N07XX59 [43534835]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
0
9
55
585
varicella, live attenuated
J07BK01 [21601362]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
0
8
79
759
—
—
—
—
0
6
55
588
Microscopic observation [Identifier] in Isolate by Gram stain
87975-9 [36305247]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
Oral and dental health check by dental hygienist or dental assistant
SAB02 [2001310280]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.03%
—
—
—
—
—
—
0
18
55
576
Ankle X-ray examination without contrast
NH1AA [2001308235]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
0
8
75
729
—
—
—
—
—
0
6
55
588
Examination of eyes and vision
Z01.0 [45566391]
1.4e+00
—
—
—
—
—
—
cases:13.33%
controls:3.66%
—
—
—
—
—
—
—
—
—
—
—
—
10
27
65
710
—
—
—
—
—
—
Ankle symptom/complaint
L16 [2002000640]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
0
20
75
717
—
—
—
—
0
5
71
701
—
Prolactin [Units/volume] in Serum or Plasma
15081-3 [3021387]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
7
55
587
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
0
8
71
698
—
Vancomycin [Mass/volume] in Serum or Plasma
20578-1 [3005715]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
75
730
—
—
—
—
—
—
drospirenone and ethinylestradiol
G03AA12 [21602485]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:1.68%
0
6
75
731
—
—
—
—
0
5
71
701
0
10
55
584
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
351 [2001600312]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
Foot/toe symptom/complaint
L17 [2002000641]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:4.21%
—
—
—
—
—
—
0
25
55
569
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
2500B [2000402295]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
0
8
75
729
—
—
—
—
—
0
5
55
589
Psychiatric treatment plan, monitoring
ICB03 [2001304100]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
metronidazole; oral, rectal
P01AB01 [21604857]
9.4e-01
—
—
—
—
—
7.0e-01
cases:6.67%
controls:2.71%
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:4.71%
5
20
70
717
—
—
—
—
—
5
28
50
566
Psychiatric treatment plan, extended/prolonged
ICB02 [2001304099]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
Dog dander IgE Ab [Units/volume] in Serum
6098-8 [3014133]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:1.18%
0
5
75
732
—
—
—
—
0
7
71
699
0
7
55
587
Abdominal pain epigastric
D02 [2002000301]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
1.2e+00
1.0e+00
—
—
—
—
5.3e-01
cases:12.00%
controls:4.07%
cases:6.33%
controls:2.35%
—
—
—
—
—
—
—
—
cases:9.09%
controls:5.56%
9
30
66
707
5
18
74
749
—
—
—
—
5
33
50
561
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.71%
cases:0.00%
controls:1.96%
—
—
—
—
—
—
cases:0.00%
controls:2.27%
cases:0.00%
controls:3.37%
0
20
75
717
0
15
79
752
—
—
—
0
16
71
690
0
20
55
574
Buprenorphine [Presence] in Urine by Screen method
93494-3 [1001926]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.09%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.53%
0
8
75
729
0
5
79
762
—
—
—
—
0
15
55
579
chloramphenicol
S01AA01 [21603554]
2.9e-01
—
—
—
—
1.2e+00
2.3e-01
cases:13.33%
controls:10.31%
—
—
—
—
—
—
—
—
cases:11.27%
controls:3.54%
cases:14.55%
controls:11.95%
10
76
65
661
—
—
—
—
8
25
63
681
8
71
47
523
Tissue transglutaminase IgG Ab [Units/volume] in Serum
32998-7 [3046870]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
7
79
760
—
—
—
—
—
Atrial fibrillation and flutter
I48 [45596206]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.17%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
0
16
75
721
—
—
—
—
0
7
71
699
—
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
0
8
55
586
topiramate; oral
N03AX11 [21604433]
—
1.0e+50
—
—
—
—
—
—
—
cases:7.59%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
6
0
73
767
—
—
—
—
—
Horse dander IgE Ab [Units/volume] in Serum
6143-2 [3010726]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.90%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
cases:0.00%
controls:1.35%
0
14
75
723
0
5
79
762
—
—
—
0
8
71
698
0
8
55
586
Psychoeducation, group
IER01 [2001304205]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
6
55
588
Disturbance of activity and attention
F90.0 [45542870]
—
—
-1.0e+50
—
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.91%
—
—
cases:0.00%
controls:1.31%
—
—
cases:0.00%
controls:3.87%
—
—
0
7
79
760
—
0
10
77
753
—
0
23
55
571
Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay
5159-9 [3007844]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
0
6
79
761
—
—
—
—
—
codeine and paracetamol
N02AJ06 [1123647]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:8.75%
—
—
—
—
—
—
0
52
55
542
Mild mental retardation, With the statement of no, or minimal, impairment of behaviour
F70.0 [45595920]
1.0e+50
1.0e+50
—
—
—
—
—
cases:9.33%
controls:0.00%
cases:7.59%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
7
0
68
737
6
0
73
767
—
—
—
—
—
simvastatin; oral
C10AA01 [21601856]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.17%
—
—
cases:0.00%
controls:1.70%
—
—
—
—
—
—
0
9
79
758
—
0
13
77
750
—
—
Telehealth
OMOP5556618 [722455]
3.1e-01
1.2e-01
—
—
—
2.4e-01
6.1e-01
cases:30.67%
controls:24.42%
cases:8.86%
controls:7.95%
—
—
—
—
—
—
cases:11.27%
controls:9.07%
cases:30.91%
controls:19.53%
23
180
52
557
7
61
72
706
—
—
—
8
64
63
642
17
116
38
478
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.17%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
75
721
—
—
—
—
—
—
Ultrasound measurement of residual urine
KC1EE [2001305918]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.49%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:2.02%
0
11
75
726
—
—
—
—
0
5
71
701
0
12
55
582
levofloxacin
S01AE05 [43534860]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
0
5
79
762
—
—
—
—
—
clindamycin; oral, parenteral
J01FF01 [21602985]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.44%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
0
18
75
719
—
—
—
—
0
8
71
698
—
Open wound of wrist and hand, part unspecified
S61.9 [45554740]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
alfuzosin; oral
G04CA01 [21602668]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.85%
—
—
—
—
—
—
0
11
55
583
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
-1.7e-01
-1.0e+50
—
—
—
—
—
cases:9.33%
controls:10.85%
cases:0.00%
controls:3.52%
—
—
—
—
—
—
—
—
—
—
7
80
68
657
0
27
79
740
—
—
—
—
—
Other psychiatric treatment contact
IGY99 [2001304323]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.68%
—
0
8
79
759
—
—
—
—
0
10
55
584
CD3+CD8+ (T8 suppressor) cells/cells in Blood
8101-8 [3007449]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
vortioxetine; oral
N06AX26 [44819158]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
6
55
588
insulin lispro; parenteral
A10AC04 [21600726]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:2.17%
cases:0.00%
controls:1.83%
cases:0.00%
controls:0.65%
—
—
cases:0.00%
controls:0.79%
cases:0.00%
controls:2.27%
—
—
0
16
75
721
0
14
79
753
0
5
79
762
—
0
6
77
757
0
16
71
690
—
diclofenac; ointment
M02AA15 [21604051]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.85%
—
—
—
—
—
—
0
11
55
583
dydrogesterone; oral
G03DB01 [21602544]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
7
55
587
More than one and less than three hours
ZXE10 [2001311401]
6.3e-01
—
—
—
—
—
1.3e+00
cases:10.67%
controls:5.97%
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:2.69%
8
44
67
693
—
—
—
—
—
5
16
50
578
Adenocarcinoma, NOS, of prostate gland
8140/3-C61.9 [44499685]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.90%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
75
723
—
—
—
—
—
—
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.22%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
75
728
—
—
—
—
—
—
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
—
—
—
—
—
—
8.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.73%
controls:5.89%
—
—
—
—
—
—
7
35
48
559
Telephone prescription or other care instructions
WZB00 [2001310884]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.73%
controls:3.03%
—
—
—
—
—
—
7
18
48
576
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
3.9e-01
—
—
—
—
—
7.1e-01
cases:9.33%
controls:6.51%
—
—
—
—
—
—
—
—
—
—
cases:14.55%
controls:7.74%
7
48
68
689
—
—
—
—
—
8
46
47
548
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
0
5
71
701
—
Treatment-related counselling outside office
SPAT1249 [2001700350]
4.8e-01
—
—
—
—
1.4e+00
1.0e+00
cases:9.33%
controls:5.97%
—
—
—
—
—
—
—
—
cases:7.04%
controls:1.84%
cases:18.18%
controls:7.24%
7
44
68
693
—
—
—
—
5
13
66
693
10
43
45
551
Cells panel - Urine sediment
58434-2 [40761535]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
roxithromycin; oral
J01FA06 [21602974]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
0
6
79
761
—
—
—
—
—
loratadine; oral
R06AX13 [21603514]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
0
5
75
732
—
—
—
—
—
0
7
55
587
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.85%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
0
21
75
716
0
5
79
762
—
—
—
—
—
Red eye
F02 [2002000400]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
7
55
587
Migraine with aura [classical migraine]
G43.1 [45562086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
6.2e-01
-1.0e+50
—
—
—
—
1.1e+00
cases:8.00%
controls:4.48%
cases:0.00%
controls:1.43%
—
—
—
—
—
—
—
—
cases:9.09%
controls:3.20%
6
33
69
704
0
11
79
756
—
—
—
—
5
19
50
575
IgG subclass 3 [Mass/volume] in Serum
2468-7 [3024139]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
pH of Specimen
17433-4 [3019225]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
BK virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
32284-2 [3000504]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
75
730
—
—
—
—
—
—
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.91%
controls:2.53%
—
—
—
—
—
—
6
15
49
579
combinations of corticosteroids
D07AB30 [21602118]
6.3e-01
5.8e-01
—
—
-1.0e+50
9.5e-01
1.1e+00
cases:16.00%
controls:9.23%
cases:6.33%
controls:3.65%
—
—
—
—
cases:0.00%
controls:0.66%
cases:7.04%
controls:2.83%
cases:20.00%
controls:7.91%
12
68
63
669
5
28
74
739
—
—
0
5
77
758
5
20
66
686
11
47
44
547
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.63%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
0
12
75
725
0
7
79
760
—
—
—
0
5
71
701
—
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
6.1e-01
—
—
—
—
1.0e+00
1.3e+00
cases:13.33%
controls:7.73%
—
—
—
—
—
—
—
—
cases:7.04%
controls:2.69%
cases:18.18%
controls:5.72%
10
57
65
680
—
—
—
—
5
19
66
687
10
34
45
560
Simple examination of mouth
SAA01 [2001310274]
1.5e-01
1.7e-01
—
—
—
4.3e-01
3.0e-01
cases:22.67%
controls:20.08%
cases:8.86%
controls:7.56%
—
—
—
—
—
—
cases:11.27%
controls:7.65%
cases:30.91%
controls:24.92%
17
148
58
589
7
58
72
709
—
—
—
8
54
63
652
17
148
38
446
Alzheimer disease with late onset
G30.1 [45552521]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
Ultrasound examination of lower leg veins
PH2AE [2001309451]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
Pure hypercholesterolaemia
E78.0 [45542771]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
felodipine; oral
C08CA02 [21601748]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:0.84%
—
0
7
79
760
—
—
—
0
7
71
699
0
5
55
589
covid-19, RNA-based vaccine
J07BN01 [954934]
3.8e-02
7.4e-01
—
—
—
—
-1.5e-01
cases:10.67%
controls:10.31%
cases:7.59%
controls:3.78%
—
—
—
—
—
—
—
—
cases:12.73%
controls:14.48%
8
76
67
661
6
29
73
738
—
—
—
—
7
86
48
508
Oncology Clinic/Center
261QX0200X [38004268]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.69%
0
20
75
717
—
—
—
—
—
0
16
55
578
Respiratory syncytial virus Ag [Presence] in Specimen
31950-9 [3001684]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
Custom moulded splint, unspecified region
TNX32 [2001308563]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
Cashew nut recombinant (rAna o) 3 IgE Ab [Units/volume] in Serum
82539-8 [42528717]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
75
729
—
—
—
—
—
—
Other viral haemorrhagic fevers, not elsewhere classified
A98 [45755322]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
75
731
—
—
—
—
—
—
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.36%
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
0
10
75
727
0
6
79
761
—
—
—
—
0
5
55
589
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.71%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
0
20
75
717
0
7
79
760
—
—
—
—
—
Contraception oral
W11 [2002001211]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.20%
0
5
75
732
0
6
79
761
—
—
—
—
0
19
55
575
Impacted cerumen
H61.2 [45562307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
0
8
55
586
One hour or less
ZXE00 [2001311394]
8.6e-01
9.3e-01
—
—
—
1.7e+00
1.2e+00
cases:17.33%
controls:8.14%
cases:7.59%
controls:3.13%
—
—
—
—
—
—
cases:7.04%
controls:1.42%
cases:12.73%
controls:4.38%
13
60
62
677
6
24
73
743
—
—
—
5
10
66
696
7
26
48
568
Hemoglobin [Mass/volume] in Arterial cord blood
30354-5 [3027901]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
Embedded teeth
K01.0 [45548133]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
75
730
—
—
—
—
—
—
Pain in joint
M25.5 [45586941]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.19%
—
—
—
—
—
—
0
13
55
581
Localized swelling, mass and lump, unspecified
R22.9 [45577788]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
Gliadin peptide IgA Ab [Units/volume] in Serum by Immunoassay
63453-5 [40766183]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
75
726
—
—
—
—
—
—
Placement of prefabricated palatal or lingual arch
SJD40 [2001310441]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:2.53%
0
20
75
717
—
—
—
—
0
5
71
701
0
15
55
579
erdosteine; oral
R05CB15 [21603394]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
7
55
587
phenoxymethylpenicillin; oral
J01CE02 [21602842]
-2.0e-02
-1.0e+50
—
—
—
—
-1.7e-01
cases:10.67%
controls:10.85%
cases:0.00%
controls:3.65%
—
—
—
—
—
—
—
—
cases:10.91%
controls:12.63%
8
80
67
657
0
28
79
739
—
—
—
—
6
75
49
519
Extensive health check-up of expecting family
SPAT1197 [2001700298]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
5
55
589
sodium chloride
B05CB01 [21601180]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
75
732
—
—
—
—
—
—
Health check-up performed during first study year in students of upper secondary schools, vocational schools etc.
SPAT1363 [2001700464]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:3.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.02%
0
25
75
712
—
—
—
—
—
0
12
55
582

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
40
158
3.59
8.39
3.7
2.9
—
—
—
0
0
42
178
3.38
7.80
4.9
4.5
—
—
—
0
0
15
27
6.36
5.97
6.7
6.0
23.47
24.56
mmol/l
0.59
15
27
10
14
7.81
4.78
2.9
2.7
17.88
16.21
%
—
10
14
11
19
6.37
4.59
3.0
2.9
92.92
91.09
%
0.58
11
19
59
376
2.43
4.37
4.2
3.8
0.00
0.00
estimate
-0.00
13
51
63
414
2.46
4.35
12.0
13.7
1.22
1.22
mmol/l
0.01
58
385
9
13
7.49
4.27
2.9
2.0
1.72
1.42
mmol/l
—
9
13
9
13
7.49
4.27
1.7
3.2
1.77
2.09
umol/l
—
9
13
58
370
2.39
4.25
4.2
3.8
0.00
0.00
estimate
-0.00
13
58
58
375
2.34
4.05
4.2
3.8
0.00
0.00
estimate
-0.00
13
56
24
104
2.73
3.99
8.8
19.0
106.25
104.33
mmol/l
1.00
24
104
34
181
2.35
3.67
4.9
3.8
0.00
0.00
estimate
-0.00
12
54
32
166
2.38
3.66
12.5
9.3
5.23
5.12
kpa
0.30
32
161
18
70
2.92
3.63
10.6
19.9
7.39
7.42
ph
—
9
38
45
273
2.20
3.53
3.4
4.1
97.50
33.25
e6/l
0.32
35
204
18
72
2.84
3.45
10.3
19.3
1.72
0.30
mmol/l
0.55
13
61
43
260
2.17
3.37
9.4
11.3
1.16
1.23
inr
0.58
36
219
0
82
0.00
3.33
0.0
1.2
—
6.33
—
0
71
0
81
0.00
3.32
0.0
1.2
—
1.32
—
0
65
42
256
2.12
3.19
4.5
3.2
0.00
0.00
estimate
-0.00
12
48
16
63
2.84
3.14
9.1
16.9
123.13
124.06
g/l
0.05
16
63
0
79
0.00
3.12
0.0
1.2
—
2.47
—
0
66
53
357
2.06
3.05
5.1
8.2
19.85
20.40
umol/l
0.02
43
340
5
5
10.43
3.01
2.6
1.8
51.29
45.60
umol/l
—
5
5
17
71
2.69
3.00
11.1
19.4
12.13
14.04
kpa
0.69
17
71
17
71
2.69
3.00
11.1
19.5
5.28
5.05
kpa
0.69
17
71
0
76
0.00
2.90
0.0
1.5
—
—
—
0
0
5
6
8.69
2.78
2.2
2.7
1.12
1.11
umol/l
—
5
6
27
145
2.19
2.78
9.0
9.2
—
—
—
0
0
48
322
1.96
2.70
4.6
5.2
64.16
74.95
e6/l
0.09
34
218
11
36
3.31
2.66
2.8
8.7
36.96
36.96
°c
0.01
11
36
6
11
5.73
2.58
5.0
3.5
—
—
—
0
0
66
500
1.98
2.54
5.5
4.1
—
—
—
0
0
34
207
1.98
2.49
3.5
4.3
—
—
—
0
0
31
183
2.02
2.48
4.9
13.8
7.36
7.37
ph
0.21
24
111
13
52
2.73
2.47
1.2
6.7
0.50
0.44
%
—
6
18
30
179
1.97
2.31
3.7
2.4
0.00
0.00
estimate
-0.00
11
48
13
54
2.62
2.31
1.9
6.9
0.00
0.00
%
—
5
18
9
30
3.20
2.21
1.6
4.4
32.89
40.50
umol/l
—
9
30
12
49
2.65
2.20
4.2
2.6
—
—
—
0
0
31
191
1.91
2.16
16.5
20.3
25.57
24.87
mmol/l
0.40
31
191
8
183
0.39
2.10
1.4
2.0
—
—
—
0
0
5
10
5.20
2.09
2.2
2.4
11.26
12.49
umol/l
—
5
10
18
93
2.15
2.01
2.0
1.8
—
—
—
0
0
28
171
1.89
1.99
10.0
14.9
—
—
—
0
0
0
50
0.00
1.95
0.0
1.1
—
5.30
—
0
39
66
525
1.79
1.91
5.7
7.0
125.10
112.65
u/l
0.52
60
491
13
60
2.35
1.87
2.0
6.3
0.50
0.71
%
—
6
24
37
251
1.76
1.87
3.2
4.0
0.77
0.28
e6/l
0.45
27
184
7
23
3.20
1.83
4.3
2.5
554.86
268.78
ug/l
—
7
23
0
47
0.00
1.76
0.0
1.1
—
8.11
—
0
35
26
162
1.82
1.72
3.0
4.0
2.08
1.51
e6/l
0.16
13
87
12
224
0.47
1.66
1.3
2.0
—
—
—
0
0
9
37
2.57
1.52
2.0
7.9
23.39
23.86
mmol/l
—
9
37
29
195
1.69
1.47
3.5
3.6
7.41
7.39
ph
1.23
21
130
9
39
2.44
1.47
19.1
30.3
25.11
23.82
mmol/l
—
9
39
27
179
1.70
1.44
4.7
3.5
1.02
1.02
kg/l
0.57
19
113
41
304
1.60
1.42
2.9
3.0
—
—
estimate
—
0
0
9
42
2.26
1.38
13.6
22.8
15.34
16.31
%
—
9
42
19
115
1.81
1.37
1.7
2.6
384.42
318.97
nmol/l
0.59
19
107
10
48
2.21
1.33
17.3
26.0
96.51
95.35
%
—
10
48
14
78
1.93
1.29
1.4
1.4
—
—
—
0
0
6
25
2.49
1.26
2.2
1.8
—
—
—
0
0
6
25
2.49
1.26
2.2
1.8
—
—
—
0
0
6
25
2.49
1.26
2.2
1.8
—
—
—
0
0
6
25
2.49
1.26
2.2
1.8
—
—
—
0
0
58
476
1.54
1.24
9.9
13.1
0.00
0.00
e9/l
0.80
53
374
34
248
1.57
1.24
3.1
3.9
—
—
estimate
—
0
0
17
107
1.71
1.08
1.5
1.6
—
—
—
0
0
10
53
1.99
1.05
4.5
23.5
0.57
0.61
%
—
10
53
9
49
1.92
1.02
19.1
25.4
0.82
1.24
%
—
9
49
10
54
1.95
1.01
4.5
23.1
0.89
1.32
%
—
10
54
0
28
0.00
0.99
0.0
1.1
—
—
—
0
0
0
28
0.00
0.99
0.0
2.0
—
7.95
—
0
6
0
32
0.00
0.97
0.0
1.2
—
—
—
0
0
0
32
0.00
0.97
0.0
1.2
—
—
—
0
0
14
87
1.71
0.93
1.6
1.8
606.44
435.68
pmol/l
—
9
80
85
780
1.68
0.93
17.1
10.4
—
—
—
0
0
8
139
0.54
0.92
1.1
1.7
—
—
—
0
0
40
320
1.42
0.89
3.4
3.6
6.37
6.27
ph
0.15
15
144
31
237
1.45
0.88
4.4
3.0
2.35
2.39
mmol/l
1.34
31
221
9
148
0.57
0.88
1.0
1.3
—
—
—
0
0
6
31
1.99
0.86
3.3
4.1
—
—
—
0
0
0
24
0.00
0.80
0.0
6.0
—
0.25
—
0
11
49
568
0.73
0.80
3.2
3.8
1.21
1.19
mmol/l
0.10
43
540
0
25
0.00
0.80
0.0
1.2
—
—
—
0
0
0
26
0.00
0.79
0.0
5.3
—
35.87
—
0
26
52
596
0.73
0.78
3.7
4.2
1.33
1.42
mmol/l
0.88
45
567
30
233
1.41
0.78
1.3
1.5
—
—
—
0
0
9
56
1.67
0.75
1.4
1.1
—
—
—
0
0
28
218
1.40
0.71
3.1
2.8
—
—
—
0
0
5
28
1.83
0.67
6.8
34.0
58.20
70.63
%
—
5
28
8
50
1.65
0.63
21.1
25.0
0.65
0.66
%
—
8
50
84
786
1.48
0.63
19.5
14.0
39.62
23.96
mg/l
2.39
72
579
0
20
0.00
0.61
0.0
1.5
—
—
—
0
0
0
20
0.00
0.61
0.0
1.4
—
—
—
0
0
0
20
0.00
0.61
0.0
1.4
—
1.26
—
0
15
38
318
1.32
0.61
6.0
7.7
—
—
—
0
0
15
107
1.47
0.59
1.3
5.7
69.51
66.24
e9/l
—
8
76
0
23
0.00
0.59
0.0
1.4
—
—
—
0
0
34
403
0.76
0.59
2.9
3.6
65.94
81.75
ug/l
0.48
29
386
55
609
0.78
0.54
4.0
4.6
2.42
2.64
mmol/l
1.27
48
579
17
221
0.72
0.54
2.2
2.7
—
—
—
0
0
6
40
1.53
0.52
3.8
5.7
—
—
—
0
0
0
15
0.00
0.41
0.0
44.7
—
163.80
—
0
15
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
8
111
0.70
0.40
1.1
1.5
—
—
—
0
0
55
502
1.22
0.38
5.4
10.6
0.59
0.57
e9/l
0.31
49
425
55
502
1.22
0.38
5.4
10.6
0.03
0.04
e9/l
0.51
49
422
42
376
1.20
0.35
5.3
11.4
—
—
—
0
0
56
601
0.84
0.32
3.4
4.4
4.23
4.45
mmol/l
1.06
50
574
56
599
0.85
0.29
4.1
3.9
6.13
5.68
mmol/l
0.73
51
561
26
227
1.20
0.27
1.7
1.9
93.83
94.51
pmol/l
0.03
13
118
20
171
1.21
0.26
4.5
5.5
—
—
—
0
0
18
153
1.22
0.24
4.1
3.3
34.89
110.73
mg/l
1.11
12
109
5
37
1.37
0.24
2.0
3.7
7.70
5.73
ug/l
—
5
23
57
602
0.87
0.22
3.8
4.0
14.92
14.69
pmol/l
0.24
51
567
55
518
1.14
0.22
5.4
11.3
0.18
0.23
e9/l
1.17
50
448
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
172.27
—
0
11
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
214.80
—
0
10
0
10
0.00
0.21
0.0
2.9
—
—
—
0
0
0
10
0.00
0.21
0.0
2.2
—
3.47
—
0
10
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
13
0.00
0.21
0.0
2.1
—
—
—
0
0
18
156
1.19
0.20
4.5
3.9
8.10
10.75
mg/mmol
0.24
12
107
0
14
0.00
0.20
0.0
4.1
—
0.52
—
0
14
51
480
1.13
0.20
5.5
10.7
0.53
0.68
%
1.00
51
457
52
490
1.13
0.20
5.2
10.5
51.91
51.64
%
0.05
52
476
51
482
1.12
0.18
5.5
10.6
2.64
3.40
%
1.74
51
457
22
198
1.14
0.16
3.2
3.8
22.58
42.54
ng/l
0.97
17
133
51
486
1.10
0.14
5.5
10.7
8.42
8.50
%
0.09
51
463
52
498
1.09
0.12
5.5
10.5
32.77
33.45
%
0.14
52
481
6
53
1.14
0.09
1.0
1.5
—
—
—
0
0
5
61
0.81
0.08
1.2
1.5
—
—
—
0
0
8
91
0.87
0.07
3.5
2.7
5.51
4.27
e9/l
—
8
80
21
198
1.08
0.06
3.0
1.7
—
—
—
0
0
34
332
1.04
0.02
1.3
1.8
0.36
2.68
u/ml
—
7
57
15
156
0.95
0.00
2.5
2.9
—
—
—
0
0
31
312
0.99
0.00
1.5
1.9
1.60
1.78
g/l
0.41
21
153
68
685
0.98
0.00
4.1
4.6
1.67
1.98
mu/l
2.26
62
648
8
89
0.89
0.00
1.3
1.4
66.50
213.60
u/ml
—
8
83
0
8
0.00
0.00
0.0
22.3
—
8.94
—
0
8
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
2.9
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
19.96
—
0
8
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
1430.71
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
3.73
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
223.83
—
0
6
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
27.80
—
0
5
0
6
0.00
-0.00
0.0
32.7
—
0.55
—
0
6
0
9
0.00
-0.00
0.0
7.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
7
78
0.89
-0.00
1.1
1.3
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint F5_SEVRET and mortality.

Females

Parameter HR [95% CI] p-value
F5_SEVRET 7.236 [4.69, 11.16] < 0.001
Birth year 0.996 [0.99, 1.0] 0.367

During the follow-up period (1.1.1998 — 31.12.2019), 263 out of 981 females with F5_SEVRET died.

Males

Parameter HR [95% CI] p-value
F5_SEVRET 5.907 [4.34, 8.03] < 0.001
Birth year 0.992 [0.98, 1.0] 0.091

During the follow-up period (1.1.1998 — 31.12.2019), 324 out of 1391 males with F5_SEVRET died.

Mortality risk

Mortality risk for people of age

years, who have F5_SEVRET.

N-year risk Females Males
1 0.712% 1.176%
5 4.535% 7.074%
10 9.503% 17.82%
15 18.507% 31.6%
20 31.77% 46.652%

Relationships between endpoints

↥

Index endpoint: F5_SEVRET – Severe mental retardation

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data